4 results about "TRAIL Protein" patented technology

The application belongs to the technical field of biomedicine, and discloses a detection kit based on a beta-trail protein monoclonal antibody and application thereof. The application provides two strains of monoclonal antibodies which specifically recognize different antigen epitopes of the beta-trail protein, have high affinity and good specificity, and can be used for detection of the beta-trail protein. The application also provides a beta-trail protein detection kit with good performance, which has a wide linear range, high precision, good repeatability and strong applicability. The detection kit prepared by using the monoclonal antibody can be applied to kidney disease screening detection, disease monitoring, prognosis evaluation and the like.

The application discloses a compound drug-loaded exosome for overcoming cancer TRAIL drug resistance and a preparation method thereof, relates to the technical field of compound nano-drug preparation, and comprises an engineered exosome and an interfering RNA targeting a natriuretic peptide receptor A gene, wherein the engineered exosome is derived from a cell capable of expressing a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and carries the TRAIL protein; the interfering RNA is loaded in the engineered exosome; and the engineered exosome and the interfering RNA synergistically act to silence the NPRA gene through the interfering RNA to overcome the drug resistance of cancer cells to TRAIL. The application can silence the NPRA gene and remodel the apoptosis sensitivity of tumor cells through multiple channels, thereby efficiently overcoming the TRAIL drug resistance.

A fusion nanoprotein is provided wherein TRAIL with a trimer structure is conjugated to a human ferritin monomer fragment and exhibits enhanced cancer targeting using a cancer-targeting peptide. The fusion protein effectively targets cancer cells when injected into a blood vessel, leading to TRAIL-induced cancer cell death. This fusion nanoprotein addresses key challenges of TRAIL proteins by improving their stability and reducing off-target effects through stable delivery of TRAIL trimers specifically to cancer tissues. The enhanced stability and targeted delivery properties make this fusion protein a promising candidate for development as an anticancer therapeutic agent.

This invention belongs to the field of biomedicine and relates to nanobodies. The amino acid sequence of the anti-trail nanobody is shown in SEQ ID No. 1. It can also be a tandem antibody composed of two or more repeating anti-trail nanobodies. The nanobody has a small molecular weight, strong tissue penetration, and high affinity. The anti-trail nanobody of this invention has good binding affinity to human trail protein, and it also exhibits good trail-DR5 pathway blocking activity, significantly reducing cerebral ischemia-reperfusion injury after cerebral infarction, and has broad clinical application prospects.